Form 4: Astrana Health Director Matthew Mazdyasni Granted Restricted Stock

Astrana Health, Inc. Director Matthew Mazdyasni was granted 6,449 shares of restricted common stock, aligning his interests with shareholders.

Summary

• Matthew Mazdyasni, a Director of Astrana Health, Inc. (ASTH), acquired 6,449 shares of the company's common stock.
• The transaction occurred on June 11, 2025, and the shares were acquired at a price of $0, indicating a grant rather than a purchase.
• These 6,449 shares are restricted stock granted under the Issuer's 2024 Equity Incentive Plan.
• The restricted shares are set to vest on the earlier of June 11, 2026, or the date of the Issuer's 2026 annual meeting of stockholders.
• Following this transaction, Mr. Mazdyasni beneficially owns a total of 14,763 shares of Astrana Health common stock, which includes the newly granted restricted shares.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While a Form 4 is primarily a disclosure of an insider transaction, the grant of restricted stock to a director is generally viewed favorably as it aligns the director's financial interests with the long-term performance of the company and its shareholders. It's a routine compensation event, not indicative of major positive or negative news.

Positives

• The grant of restricted stock to a director aligns management's interests with those of shareholders, as the value of the shares is tied to the company's performance.
• The transaction is part of the company's 2024 Equity Incentive Plan, indicating a structured approach to executive compensation and retention.

Future Outlook

The 6,449 restricted shares granted to Director Matthew Mazdyasni are scheduled to vest on the earlier of June 11, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, indicating a future milestone for these equity holdings.

Management Comments

• The transaction reflects a grant of restricted shares pursuant to the Issuer's 2024 Equity Incentive Plan, a standard mechanism for executive compensation and alignment.

Industry Context

This Form 4 filing details a routine insider transaction, specifically a restricted stock grant to a director. Such grants are common practice across various industries as a means of incentivizing long-term performance and aligning the interests of company leadership with shareholders. It does not provide information on broader industry trends or competitive landscape.

Comparison to Industry Standards

• The grant of restricted stock as part of an equity incentive plan is a standard compensation practice for directors and executives across publicly traded companies, aligning their long-term interests with shareholder value creation.
• The vesting schedule (approximately one year from grant or the next annual meeting) is within typical industry ranges for such grants, which often vary from one to five years depending on the company's specific compensation philosophy and retention goals.

Corporate Governance

Related Party Transactions

• The acquisition of 6,449 shares of common stock by Matthew Mazdyasni, a Director of Astrana Health, Inc., constitutes a related party transaction as it involves an insider of the company.

Stakeholder Impact

• Shareholders: The grant of restricted stock to a director aligns the director's financial incentives with the company's long-term performance, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The 6,449 restricted shares granted to Matthew Mazdyasni will vest on the earlier of June 11, 2026, or the date of the Issuer's 2026 annual meeting of stockholders.

Key Dates

Keywords

Astrana Health, ASTH, SEC Form 4, Restricted Stock, Equity Incentive Plan, Insider Transaction, Director Compensation, Stock Grant